Trial Profile
Phase 1/2 Study of Intravenous or Intrapleural Administration of a Serotype rh.10 Replication Deficient Adeno-associated Virus Gene Transfer Vector Expressing the Human Alpha-1 Antitrypsin cDNA to Individuals With Alpha-1 Antitrypsin Deficiency
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 09 Oct 2023
Price :
$35
*
At a glance
- Drugs ADVM 043 (Primary) ; ADVM 043 (Primary)
- Indications Alpha 1-antitrypsin deficiency
- Focus Adverse reactions; First in man
- Acronyms ADVANCE
- Sponsors Adverum Biotechnologies
- 16 Jul 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Aug 2019.
- 01 Nov 2018 According to an Adverum Biotechnologies media release, based on the data of this study, the Company announced its decision to discontinue the development of ADVM-043, the data did not demonstrate the potential to reach M-protein threshold levels of 11µM.
- 01 Nov 2018 Status changed from recruiting to discontinued, according to an Adverum Biotechnologies media release.